Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
stocks
Chart of the Week: Why ASX tech is poised for a comeback
The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,381.40 | 9.10 | -0.10% |
| CAC 40 | 8,691.95 | 17.01 | 0.20% |
| DAX 40 | 26,467.79 | 136.72 | 0.52% |
| Dow JONES (US) | 53,770.27 | 21.58 | -0.04% |
| FTSE 100 | 10,809.64 | 23.51 | -0.22% |
| HKSE | 25,396.51 | 43.66 | -0.17% |
| NASDAQ | 26,588.49 | 143.04 | 0.54% |
| Nikkei 225 | 68,308.59 | 784.53 | 1.16% |
| NZX 50 Index | 13,825.30 | 87.64 | 0.64% |
| S&P 500 | 7,748.50 | 20.30 | 0.26% |
| S&P/ASX 200 | 9,188.50 | 4.40 | -0.05% |
| SSE Composite Index | 3,926.96 | 19.71 | -0.50% |